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steoporosis leads to bone mass reduction while periodontal
isease causes resorption of the alveolar bone. Both conditions
ave some common risk factors like smoking, poor nutri-
ional status, age and immune deﬁciency.1 The bone changes
aused by osteoporosis seem to aggravate periodontal dis-
ase, however, the pathogenesis of that process is not yet fully
nderstood.2
A possible pathway in which systemic bone loss may lead
o more  severe periodontal destruction is that the reducedPlease cite this article in press as: Penoni DC, et al. Possible links betwe
http://dx.doi.org/10.1016/j.rbre.2016.03.004
one mineral density (BMD), caused by osteoporosis in the
lveolar bone, may facilitate local bone resorption caused by
he periodontal disease.3 Another possibility is that systemic
actors of bone remodeling could modify local tissue response
o periodontal infection. Accordingly, individuals with sys-
emic bone loss who  have periodontitis may react differently
o the increased production of cytokines and inﬂammatory
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icenses/by-nc-nd/4.0/).mediators, therefore presenting more  severe periodontal
disease.3
Periodontitis is an infection caused by components of the
oral microbiota. Host inﬂammatory-immunologic responses
to the periodontal microorganisms are responsible for most of
the observed tissue damage, like periodontal attachment loss
and alveolar bone loss.4 Although curable at its early stage,
periodontitis remains one of the most common causes of tooth
loss. Therefore, prevention and early detection of periodontal
disease are essential to reduce the damages it implies.4
Some systemic conditions and behaviors, like poorly con-
trolled diabetes, obesity, smoking and alcohol abuse, among
others, may modify periodontal disease features. An inade-
quate dietary consumption of calcium and vitamin D may
also represent a modiﬁable risk factors for this disease. Osteo-
porosis has been related to the severity of periodontal disease,
but full explanation for this relationship is still lacking.1,2 The
aim of this study is to review the literature on the associationen osteoporosis and periodontal disease. Rev Bras Reumatol. 2016.
between osteoporosis and periodontal disease.
e under the CC BY-NC-ND license (http://creativecommons.org/
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The  biological  plausibility  of  the  association
between  periodontal  disease  and  osteoporosis
The pathogenesis of periodontal disease is a complex process
because it involves host immune response to the subgingival
bioﬁlm.4 Periodontitis is associated with increased recep-
tor activator of nuclear factor kappa- ligand (RANKL) and
decreased osteoprotegerin (OPG) levels in gingival tissue
and biological ﬂuids, including saliva and gingival crevicu-
lar ﬂuid, thus resulting in increased RANKL/OPG ratio.5 The
involvement of RANKL and OPG system is also well estab-
lished in the pathogenesis of postmenopausal osteoporosis.6
Clinical studies have reported signiﬁcant higher serum lev-
els of RANKL in postmenopausal women with periodontal
disease compared to matched subjects with periodontal
health.6
The increased production of proinﬂammatory cytokines,
such as interleukin IL-1, IL-6, tumor necrosis factor- (TNF-
) and RANKL, are important factors in the pathogenesis and
progression of periodontal disease and osteoporosis.6,7 As
such, modulation of the expression of these cytokines may
be a possible link between inﬂammation and bone resorption
in osteoporosis and periodontal disease.6
Estrogen deﬁciency has been considered a key factor for the
development of osteoporosis.8 Furthermore, estrogen inﬂu-
ences the function of human periodontal ligament cells
causing an increase in the OPG expression and a decrease
in RANKL. Accordingly, that hormone may play an important
protective role in the antiresorptive effects on human alveolar
bone.9 The inﬂuence of serum estrogen in periodontal status
of women in early menopause was identiﬁed in a longitudinal
study.10 The authors observed that women with normal estro-
gen levels presented more  bioﬁlm than those suffering from
estrogen deﬁciency; however they did not show increased gin-
gival inﬂammation. These ﬁndings suggest that estrogen may
have an inhibitory effect on gingival inﬂammation in patients
with periodontits.10
Estrogen importance to maintain of osteogenic differenti-
ation through estrogen receptors in the periodontal ligament
cells has been reported.11 Animal studies have analyzed
the inﬂuence of estrogen deﬁciency on the alveolar bone
mass.12,13 A decrease in the alveolar bone mineral density was
observed in sheep, six months after ovariectomy.12 It has been
suggested that the reduction of alveolar crest height observed
in estrogen-deﬁcient animals could result from higher con-
centrations of Il-6 within the gingiva and the adjacent bone.12
Furthermore, increased bone loss was detected in the femur
and the alveolar bone of ovariectomized rats when an ani-
mal  model induced by a combination of both periodontitis and
osteoporosis was used.13 As a result, it has been conjectured
that postmenopausal osteoporosis may act as a risk factor for
periodontal disease.13
Evidences  of  the  effects  of  osteoporosis  inPlease cite this article in press as: Penoni DC, et al. Possible links betwe
http://dx.doi.org/10.1016/j.rbre.2016.03.004
periodontal  condition
Indeed most studies that evaluated the association of low
systemic BMD  with alveolar bone loss showed signiﬁcant 1 6;x  x x(x x):xxx–xxx
positive results.1,3 Systemic bone loss, for instance, showed
a strong relationship with interproximal alveolar bone
loss in postmenopausal women with osteopenia, thus
showing that it may be a risk indicator for periodontal
destruction.3
Cross-sectional studies with large sample sizes from the
Women’s Health Initiative Observational Study (WHIOS) indi-
cated that the loss of alveolar crestal height is 230% higher
for women with osteoporosis as compared with women with
normal T-score, with increased loss for women aged over 70.
Overall, there was more  than 3-fold increase in the odds of
worse alveolar crestal height in subjects with T-scores con-
sistent with osteoporosis.14 For postmenopausal women aged
less than 70 years, systemic BMD and oral infection indepen-
dently inﬂuenced oral bone loss.15
A study comparing the periodontal status of women with
and without osteoporotic fractures revealed that fractured
postmenopausal women have lost more  teeth and presented
more  advanced attachment loss.16
Studies assessing the association between osteoporosis
and periodontal disease differ widely in their methodol-
ogy, using samples with different selection criteria, social
and demographic characteristics, techniques for periodontal
examination and BMD assess. Data analysis also varies and do
not always control for confounding factors. The lack of stan-
dardization for these studies may explain the discrepancies
observed among the results they presented.1,2 Studies with
larger samples and standardized diagnoses for osteoporosis
and periodontal disease are needed to clarify whether osteo-
porosis is a risk factor to periodontal disease and, if so, to what
extent.2
The  inﬂuence  of  treatment  of  osteoporosis  in
periodontal  condition
Systemic osteoporosis, low dietary calcium and low vitamin D
levels may inﬂuence periodontal status and may be associated
with tooth loss.2 It has been reported that periodontal disease
is more  common in women with osteoporosis and is associ-
ated with lower vitamin D level.6 Accordingly, awareness of the
systemic bone condition of a dental patient together with the
knowledge of patient’s intake of calcium and vitamin D, may
be important to understand periodontal status and improve
oral health.2
For subjects receiving maintenance therapy, a trend
was observed indicating that those receiving vitamin D
and calcium supplements have better periodontal health
than those who do not have that.17 Such a supplemen-
tation of calcium and vitamin D may also imply an
increase in mandibular bone mass for postmenopausal
women.18 Furthermore, a cross-sectional study identiﬁed an
association between plasma 25-hydroxyvitamin D concen-
trations and periodontal status among 920 postmenopausal
women and found it to be inversely associated with vita-
min  D levels, gingival bleeding and chronic periodontal
19en osteoporosis and periodontal disease. Rev Bras Reumatol. 2016.
disease.
Several options are available for pharmacological preven-
tion and treatment of osteoporosis, combined with the use
of calcium and vitamin D. Among them, bisphosphonates
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as shown to be very effective.20 Additionally, it has been
bserved that the use of bisphosphonates in conjunction
ith conventional periodontal therapy looks promising.21
n particular, alendronate treatment improved periodontal
isease and bone turnover in postmenopausal women.22 The
igniﬁcant reduction in RANKL/OPG in gingival ﬁbroblasts
s on par with effects on osteoblasts.23 Accordingly, that
ay play a key role in favoring inhibition of alveolar bone
esorption.23
The association of osteonecrosis of the jaws with the use
f bisphosphonates has been concerning dentists. However,
ntiresorptive therapy for low bone mass represents a low
isk for developing antiresorptive agent-induced osteonecro-
is of the jaw.24 On the other hand, osteoporosis is responsible
or considerable morbidity and mortality. Accordingly, the
eneﬁts provided by antiresorptive therapy outweigh the
ow risk it brings of developing osteonecrosis of the jaw.24
urthermore, untreated periodontal disease in patients under-
oing bisphosphonates therapy may lead to a higher risk of
steonecrosis of the jaws. As such, monitored dental care
s recommended in order to maintain a healthy periodontal
tatus.25
onclusion
ealth care professionals and patients alike must be made
ware that prevention of osteoporosis may be beneﬁcial
ot only for maintaining bone health alone, but also for
eriodontal health. Accordingly, it highlights the role of mul-
idisciplinary teams in supporting health. Dentists should
efer patients to a doctor to enforce the treatment of
steoporosis. Likewise, doctors should feel comfortable to
efer patients to a dentist for prevention and evaluation
f periodontal condition. By doing so, the risk for devel-
ping osteoporosis and severe periodontal disease could be
inimized.
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